Relay Therapeutics prices $275M public offering of common stock at $12/share
Relay Therapeutics has priced a public offering of 22,916,667 shares of its common stock at $12.00 per share. The gross proceeds from this offering are expected to be approximately $275 million, with the close anticipated around May 28, 2026. This financial move aims to raise capital for the company.
Relay Therapeutics (RLAY) Is Up 6.9% After Zovegalisib Phase 2 Data And Equity Raise - Has The Bull Case Changed?
Relay Therapeutics shares rose after the company completed a $275 million equity offering and released positive Phase 2 data for zovegalisib in vascular anomalies. This data, combined with the equity raise, strengthens the company's financial position ahead of its costly Phase 3 breast cancer program. While the stock may be trading above its estimated fair value due to ongoing cash burn and future dilution risks, the company is leveraging zovegalisib for both oncology and rare disease indications.
Relay Therapeutics Launches $12-Per-Share Equity Offering Under Jefferies, TD; Nets About $297 Million
Relay Therapeutics has launched a public offering of 22,916,667 shares of common stock at $12.00 per share, with Jefferies and TD Securities acting as underwriters. The underwriters fully exercised their 30-day option for an additional 3,437,500 shares, bringing the total net proceeds to approximately $296.8 million. The offering is expected to close on May 22, 2026.
Relay Therapeutics (NASDAQ: RLAY) prices $296.8 million public stock offering
Relay Therapeutics has priced an underwritten public offering of 22,916,667 shares of common stock at $12.00 per share, with underwriters fully exercising an option for an additional 3,437,500 shares. The company expects net proceeds of approximately $296.8 million from this offering, which is set to close on May 22, 2026. This capital raise, conducted through a shelf registration, will increase the company's cash resources but also result in dilution for existing shareholders.
Relay Therapeutics prices $275M public offering of common stock at $12/share
Relay Therapeutics has priced a public offering of common stock, aiming to raise $275 million. The shares are being offered at $12 per share. This financial move is expected to provide capital for the company's operations and development.
Relay Therapeutics (RLAY) Launches $275M Public Offering at $12 Per Share
Relay Therapeutics (RLAY) has commenced a public offering of 22.92 million shares at $12.00 each, aiming to raise approximately $275 million to fund its precision medicine pipeline. Despite a strong financial position, the clinical-stage biotech firm has a low GF Score of 46/100 and is considered significantly overvalued, with insider selling of $0.7 million in the last three months. Investors are advised to exercise caution and monitor the company's progress closely.
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
Relay Therapeutics, a clinical-stage precision medicine company, has announced the pricing of an underwritten public offering of 22,916,667 shares of its common stock at $12.00 per share, aiming to raise approximately $275 million before deductions. The company also granted underwriters a 30-day option to purchase additional shares. The offering, managed by several joint book-running managers, is expected to close around May 22, 2026.
Relay Therapeutics Prices $275 Mln Offering Of Shares At $12 Per Share
Relay Therapeutics has priced a public offering of 22.92 million shares of common stock at $12 per share, aiming to raise approximately $275 million. The company also granted underwriters a 30-day option to purchase an additional 3.44 million shares. The offering is expected to close around May 22, 2026, with major financial institutions acting as joint book-running managers.
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
Relay Therapeutics, Inc. announced the pricing of a public offering of 22,916,667 shares of its common stock at $12.00 per share, aiming to raise approximately $275 million in gross proceeds. The company also granted underwriters an option to purchase an additional 3,437,500 shares. The offering is expected to close around May 22, 2026, with Jefferies, TD Cowen, Goldman Sachs & Co. LLC, and Guggenheim Securities acting as joint book-running managers.
Relay Therapeutics launches $175M public stock offering
Relay Therapeutics has announced a public offering of common stock aiming to raise $175 million. The company plans to grant underwriters a 30-day option to purchase an additional 15% of the shares offered. This strategic move is intended to secure additional capital for the pharmaceutical company.
Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies - Slideshow
Relay Therapeutics, Inc. discussed initial clinical data for Zovegalisib in vascular anomalies, sharing a slide deck related to the event. The information was published by Relay Therapeutics and reported by SA Transcripts.
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $20 to $27
This article provides a quick look at today's ratings for Relay Therapeutics (RLAY.US), noting a share price forecast ranging from $20 to $27. It implies that these ratings are recent and offer a current perspective on the company's valuation.
Relay Therapeutics launches $175M public stock offering
Relay Therapeutics has announced a public stock offering aiming to raise $175 million. The biotechnology company is looking to secure additional capital through this offering to support its operations and research efforts.
A Look At Relay Therapeutics (RLAY) Valuation After Recent Share Price Pullback
Relay Therapeutics (RLAY) has seen a recent share price pullback, dropping 28% in the past month, despite year-to-date gains. The company, a clinical-stage precision medicines firm, reported US$10.68m in revenue and a US$272.71m net loss, with a market value of about US$2.32b. Its P/B ratio of 3.6x is higher than the US biotech sector average but lower than closer peers, suggesting a premium valuation that investors should consider against the backdrop of ongoing losses and pipeline risks.
Relay Therapeutics reports promising Phase 2 zovegalisib data
Relay Therapeutics announced promising initial Phase 2 ReInspire data for its drug zovegalisib in PIK3CA-driven vascular anomalies, showing a 60% volumetric response rate and broad lesion reduction. The drug demonstrated favorable safety and patient-reported outcomes, supporting chronic dosing and guiding further expansion cohorts. This positive data reinforces zovegalisib's potential in rare vascular anomalies and broader development efforts in genetic disease and breast cancer.
Cancer-drug developer Relay Therapeutics plans $175M stock sale
Relay Therapeutics (Nasdaq: RLAY) has announced an underwritten public offering of $175 million of common stock, with underwriters having a 30-day option to purchase an additional 15%. This offering is expected to be dilutive for existing shareholders as all shares are newly issued by the company. Historically, similar offerings by Relay Therapeutics have led to negative market reactions, with an average stock price decline of 9.6%.
Relay Therapeutics Announces Proposed Public Offering of Common Stock
Relay Therapeutics, Inc. has commenced an underwritten public offering of $175 million of its common stock. The company also plans to grant underwriters a 30-day option to purchase an additional 15% of the shares. Jefferies, TD Cowen, Goldman Sachs & Co. LLC, and Guggenheim Securities are serving as joint book-running managers for the offering.
Relay Therapeutics Announces Proposed Public Offering of Common Stock
Relay Therapeutics, a clinical-stage precision medicine company, has announced a proposed underwritten public offering of $175 million of its common stock. The company also intends to grant underwriters an option to purchase an additional 15% of shares offered. The offering is subject to market conditions and will be sold by Relay Therapeutics with Jefferies, TD Cowen, Goldman Sachs & Co. LLC, and Guggenheim Securities acting as joint book-running managers.
Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders
Relay Therapeutics has announced positive early Phase 2 data for its investigational drug zovegalisib in treating rare vascular anomalies caused by PIK3CA mutations. The data showed significant lesion reduction and symptomatic improvement in patients, supporting further development, including expansion cohorts for varying dosages and ongoing Phase 3 trials for breast cancer. Following the news, Relay Therapeutics' shares saw a notable increase.
Relay Therapeutics shares jump after positive vascular anomalies trial results (RLAY)
Relay Therapeutics shares surged 15% after promising early Phase 2 trial results for their drug zovegalisib in treating PIK3CA-driven vascular anomalies. The study ReInspire showed a 60% volumetric response rate at 12 weeks, with no patient discontinuations due to adverse events. The company is now expanding dose cohorts and also advancing the drug for use in oncology.
Relay Therapeutics reports 60% volumetric response in Phase 2 ReInspire zovegalisib trial
Relay Therapeutics announced positive initial Phase 2 ReInspire data for zovegalisib, showing a 60% volumetric response rate and good safety in patients with PIK3CA-driven vascular anomalies. Both 100mg and 300mg BID doses were well-tolerated with no discontinuations due to adverse events, leading to improved clinical outcomes. The 400mg BID dose was deprioritized due to safety concerns.
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential For Differentiated Safety And Efficacy In Patients With PIK3CA-Driven Vascular Anomalies
Relay Therapeutics has announced initial clinical data for Zovegalisib, suggesting its potential for differentiated safety and efficacy in treating patients with PIK3CA-driven vascular anomalies. This news highlights the company's progress in developing therapies for these conditions. The brief article, distributed by Refinitiv and Reuters, indicates positive early findings for the drug.
Drug shrinks vascular malformations in 60% of patients in early Relay trial
Relay Therapeutics (RLAY) announced positive initial Phase 2 ReInspire data for its drug zovegalisib in treating PIK3CA-driven vascular anomalies, showing a 60% volumetric lesion response at 12 weeks, which increased to 65% after the data cut-off. The study also reported high rates of investigator- and patient-reported clinical improvement (89% and 79%, respectively) and a favorable safety profile supporting chronic dosing. This promising data indicates zovegalisib's potential for differentiated safety and efficacy, leading to a significant 10.55% surge in RLAY's stock price following the announcement.
Relay Therapeutics Announces Initial Clinical Data
Relay Therapeutics has announced promising initial clinical data from its Phase 2 ReInspire trial for zovegalisib in patients with PIK3CA-driven vascular anomalies. The data showed a 60% volumetric response rate at 12 weeks, with 89% and 79% of patients achieving clinical improvement based on investigator and patient-reported outcomes, respectively. The safety profile supports chronic dosing, with expansion cohorts now open for adults and adolescents, indicating potential for zovegalisib to significantly improve treatment for this underserved population.
Relay Therapeutics, Inc. Stock 12‑Month Price Target Raised to $21.25, Implies 74% Upside
Relay Therapeutics, Inc.'s stock has seen its average 12-month price target increase from $21 to $21.25, based on estimates from 12 analysts. This new target suggests a potential upside of approximately 74% from the May 15 closing price. The consensus rating from 13 analysts remains a "Buy," with strong analyst support.
Relay Therapeutics (RLAY) price target increased by 14.03% to 21.42
The price target for Relay Therapeutics (RLAY) has been increased by 14.03% to 21.42. This update suggests a more optimistic outlook for the company's stock value among analysts.
Relay Therapeutics, Inc. - Common Stock (NQ: RLAY)
This article provides recent news headlines concerning Relay Therapeutics, Inc. (NASDAQ: RLAY) stock, including analyst upgrades and downgrades, stock price movements, earnings previews, and clinical data announcements from various dates in 2022 and 2023. It also includes the current delayed stock price and performance for RLAY.
Relay Therapeutics (RLAY) price target increased by 14.03% to 21.42
This article reports that the price target for Relay Therapeutics (RLAY) has been increased by 14.03%. The new price target is set at 21.42. No additional details are available in the provided content.
Point72 Reports Zero Ownership in Relay Therapeutics (RLAY)
Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen have filed an amended Schedule 13G/A, reporting 0% beneficial ownership of Relay Therapeutics (RLAY) common stock as of March 31, 2026. This amendment confirms their stake is below the 5% reporting threshold, indicating no reportable holdings. The filing details show zero voting and dispositive power for the entities and individual involved.
Relay Therapeutics CFO Catinazzo sells $227,840 in stock
Relay Therapeutics CFO Thomas Catinazzo sold 17,717 shares of common stock for $227,840 on May 14, 2026, executed via a Rule 10b5-1 trading plan. This sale occurred after the stock's significant surge over the past year, with InvestingPro suggesting it's currently overvalued. Despite this, several analyst firms recently raised their price targets for Relay Therapeutics due to positive developments in its drug trials.
Insider Sell Alert: Thomas Catinazzo Sells Shares of Relay Thera
Thomas Catinazzo, CFO of Relay Therapeutics Inc, sold 17,717 shares of the company on May 14, 2026. This transaction adds to a history of 19 insider sells and no buys over the past year. With the stock trading at $12.86 against a GF Value of $3.81, GuruFocus assesses Relay Therapeutics Inc as significantly overvalued.
Relay Therapeutics (RLAY) surges 16.4%: Is this an indication of further gains?
Relay Therapeutics (RLAY) experienced a significant 16.4% stock price surge, leading investors to question if this upward trend will continue. The article title suggests an analysis of whether this gain indicates further positive movements for the company's stock.
Relay Therapeutics (RLAY) CFO sells 17,717 shares in planned trade
Relay Therapeutics (RLAY) Chief Financial Officer Thomas Catinazzo sold 17,717 shares of common stock at a weighted average price of $12.86 per share, totaling approximately $228,000. This transaction was conducted under a Rule 10b5-1 trading plan adopted in October 2025. Following the sale, Catinazzo directly holds 195,178 shares, which include restricted stock units.
Relay Therapeutics CFO Catinazzo sells $227,840 in stock
Relay Therapeutics CFO Thomas Catinazzo sold 17,717 shares of common stock for $227,840 on May 14, 2026, under a Rule 10b5-1 trading plan. The sale followed a significant stock surge, and Catinazzo now holds 195,178 shares. The company has also recently received multiple price target increases from analysts due to positive developments in its drug pipeline, particularly for zovegalisib in breast cancer treatment.
Thomas J. Catinazzo (RLAY) reports multiple 10b5-1 sales totaling tens of thousands of shares
Thomas J. Catinazzo has filed a Form 144 to report multiple proposed sales of Relay Therapeutics (RLAY) common stock under Rule 144 via 10b5-1 plans. The filing details several sales on different dates in March and April 2026, collectively representing tens of thousands of shares. These sales are considered procedural filings to notify the market of planned transactions and do not confirm final settlement.
How Relay’s Phase 3 Zovegalisib Breast Cancer Push Could Reshape Relay Therapeutics’ (RLAY) Investment Story
Relay Therapeutics (RLAY) is advancing its drug zovegalisib into Phase 3 trials for PI3Ka-mutated, HR+/HER2- metastatic breast cancer, in combination with Pfizer’s atirmociclib. Despite recent financial losses and potential share dilution, the company's Q1 results showed promising data for the drug, which could significantly impact its investment narrative. The move highlights both the potential for a large precision oncology market and the considerable financial risks involved in late-stage drug development.
Relay Therapeutics, Inc. (NASDAQ:RLAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
This article analyzes the revised consensus forecasts for Relay Therapeutics (NASDAQ: RLAY) following its latest earnings report, noting a more conservative outlook from analysts. While the near-term revenue expectations remain largely stable, there's a downward revision in profit estimates. The article suggests this shift implies analysts anticipate Relay will intensify its investment in growth at the expense of immediate profitability.
Relay Therapeutics (RLAY) Q1 Loss Of US$73.3 Million Tests Growth At A Loss Narrative
Relay Therapeutics (RLAY) reported a Q1 2026 net loss of US$73.3 million on US$3 million in revenue, continuing its pattern of being a revenue-generating but loss-making biotech company. Despite trailing losses of US$272.7 million and no near-term profitability, analysts forecast significant revenue growth of about 63.9% annually. The company's P/B ratio of 3.9x is higher than the industry average, with analysts projecting a 62.5% upside, leading to a debate between bulls focusing on growth and bears on persistent losses and funding needs.
Relay Therapeutics, Inc. (RLAY) reports Q1 loss, lags revenue estimates
Relay Therapeutics (RLAY) reported a wider-than-expected loss for the first quarter of 2026, with a net loss of $0.66 per share. The company also missed revenue estimates, recording $1.64 million compared to the anticipated $2.01 million. Despite this, the stock saw a premarket gain of 0.23%.
Relay Therapeutics (RLAY) Q1 Loss Of US$73.3 Million Tests Growth At A Loss Narrative
Relay Therapeutics (RLAY) reported a Q1 2026 net loss of US$73.3 million on US$3 million in revenue, continuing its "growth at a loss" profile. Analysts forecast significant revenue growth (63.9% annually) but do not expect profitability within the next three years. The stock currently trades at a P/B of 3.9x with an implied 62.5% upside based on analyst price targets, sparking debate between supporters focusing on growth and critics concerned about persistent losses and funding needs.
Relay Therapeutics Q1 Loss Narrows, Revenue Fall
Relay Therapeutics reported a narrower net loss for the first quarter of $66.4 million, or 54 cents per share, compared to $85.0 million, or 92 cents per share, in the prior year. However, the company's collaboration revenue fell significantly to $0.4 million from $10.6 million year-over-year. Research and development expenses decreased while general and administrative expenses remained stable.
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
Relay Therapeutics announced its Q1 2026 financial results and corporate updates, highlighting a FDA Breakthrough Therapy designation for zovegalisib in advanced breast cancer. The company also reported promising clinical data for zovegalisib's triplet combination in breast cancer and initiated a Phase 1/2 trial for RLY-8161. Relay Therapeutics ended the quarter with $642.1 million in cash, projecting funding into 2029.
Relay Therapeutics, Inc. (RLAY) reports Q1 loss, lags revenue estimates
Relay Therapeutics Inc. (RLAY) reported a wider-than-expected loss for the first quarter of 2026, with a loss of $0.62 per share against an anticipated loss of $0.58 per share. The company also missed revenue estimates, reporting $2.51 million compared to a projected $2.55 million. Despite the financial misses, the company's adjusted net loss per share improved from the previous year, and it highlighted progress in its RLY-2608 and RLY-4008 programs.
[10-Q] Relay Therapeutics, Inc. Quarterly Earnings Report
Relay Therapeutics, Inc. has filed its Quarterly Report (10-Q) for the period ended March 31, 2026. The report details the company's financial condition, including net losses of $73.3 million for the first quarter of 2026, and an accumulated deficit of $2.1 billion. The company anticipates its current cash, cash equivalents, and investments of $642.1 million will fund operations into 2029, but emphasizes the need for significant additional funding to support ongoing research, development, and potential commercialization efforts for its product candidates like zovegalisib.
Goldman Sachs Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $22
Goldman Sachs has reiterated its Buy rating for Relay Therapeutics (RLAY.US) and maintained its price target at $22. This indicates a continued positive outlook from the investment bank regarding the company's stock performance.
Earnings Flash (RLAY) Relay Therapeutics, Inc. Reports Q1 Revenue $3.0M, Vs. FactSet Est of $5.6M
Relay Therapeutics, Inc. (RLAY) announced its Q1 revenue was $3.0 million, falling short of the FactSet estimate of $5.6 million. This earnings flash provides the key financial update for the quarter.
Relay breast cancer drug gets FDA breakthrough, Phase 3 next
Relay Therapeutics reported Q1 2026 financial results, including $3.0M revenue and a net loss of $73.3M, and significant corporate updates. The FDA granted Breakthrough Therapy designation for zovegalisib in PIK3CA-mutant HR+/HER2- advanced breast cancer, with Phase 3 trials planned for early 2027. The company also announced 11.1-month median progression-free survival for zovegalisib and initiated a Phase 1/2 trial for RLY-8161, stating current cash reserves of $642.1M are sufficient to fund operations into 2029.
Relay Therapeutics Q1 2026 earnings preview
This article provides a preview of Relay Therapeutics' Q1 2026 earnings. Since the full content was not provided, specific details of the preview are unavailable.
Relay Therapeutics Inc (RLAY) Stock News & Articles
This article provides an overview of Relay Therapeutics Inc (RLAY), a biotechnology company specializing in small molecule therapies for cancer and genetic diseases. It highlights the company's robust pipeline, including key drug candidates RLY-4008 and RLY-2608, and its collaboration with Genentech. The article also includes current stock data and mentions a related article suggesting clinical-stage biotechs under $30 with solid cash runways.
Relay Therapeutics (RLAY) Is Down 14.9% After Zovegalisib Triplet Data And Phase 3 Plans With Pfizer – Has The Bull Case Changed?
Relay Therapeutics' stock dropped 14.9% following the release of encouraging Phase 1/2 data for zovegalisib in breast cancer and plans for a Phase 3 trial with Pfizer. The company is also seeking to increase its authorized common stock, which could fund growth but also heighten dilution risk for investors. Analysts are optimistic about Relay's precision oncology platform, but the potential for shareholder dilution remains a key consideration for its investment narrative.
